Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

Roflumilast Use in COPD

Patient Selection Criteria

  • The European Respiratory Society suggests that roflumilast should be used in patients with severe or very severe airflow obstruction and a history of exacerbations despite optimal inhaled therapy 1, 2
  • Patients with chronic bronchitis phenotype and a history of exacerbations may benefit from roflumilast, according to the European Respiratory Society and the American College of Chest Physicians 1, 2, 3
  • The Canadian Thoracic Society guideline recommends roflumilast for patients with chronic bronchitis phenotype at high risk of exacerbations who have moderate to high symptom burden and impaired lung function 4, 5

Clinical Benefits

  • Roflumilast reduces the number of moderate or severe exacerbations per patient-year, with a rate ratio of 0.85 (95% CI 0.78-0.91), as reported by the European Respiratory Society 6
  • Roflumilast decreases the proportion of patients who develop exacerbations, with a risk ratio of 0.85 (95% CI 0.78-0.94), according to the European Respiratory Society 6
  • Roflumilast prolongs time to next exacerbation, with a hazard ratio of 0.88 (95% CI 0.81-0.96), as found by the European Respiratory Society 6
  • Roflumilast modestly improves lung function, with increases in FEV1 and FVC, as reported by the European Respiratory Society 6

Common Side Effects and Precautions

  • Patients receiving roflumilast are more likely to experience diarrhea, nausea, weight loss, psychiatric disorders, and sleep disturbance, with increased risk ratios, as reported by the European Respiratory Society 1, 7
  • Higher discontinuation rates due to adverse effects occur with roflumilast compared to placebo, with a risk ratio of 1.80, according to the European Respiratory Society 1, 7